merck kgaa springworks - Search News

News

Merck, SpringWorks

Reuters on MSN · 3d

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

Bloomberg on MSN · 4d

Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence

Merck KGaA agreed to buy SpringWorks Therapeutics Inc., a maker of medicines for cancer and rare diseases, to boost its health-care division. The purchase price of $47 per share in cash represents an equity value of about $3.

Chemistry World · 2d

Merck KGaA to buy cancer specialist SpringWorks

Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease therapies to its pipeline. Merck will pay $47 per share of SpringWorks, making the deal worth $3.9 billion (£2.9 billion), or $3.4 billion accounting for SpringWorks’ outstanding cash and debt.

3d

SpringWorks: Acquired By Merck KGaA Based On Rare Tumor Targeting Drugs Like OGSIVEO

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

2d

Stamford-based drug developer for rare cancers and tumors sold for $3.9 billion to German company

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

5d

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results